Sugi Predict

Sugi Predict / Compounds / SCHEMBL2179543

SCHEMBL2179543

SCHEMBL2179543

Nc1c(OC2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cccc1C(=O)C[C@H](N)C(=O)O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC28A3 Q9HAS3 2/20 0.51
▸ SLC5A1 P13866 3/20 0.50
▸ KDM4E B2RXH2 3/20 0.50
▸ TDP1 Q9NUW8 3/20 0.50
▸ HIF1A Q16665 2/20 0.50
▸ SLC5A2 P31639 1/20 0.50
▸ USP2 O75604 4/20 0.43
▸ HKDC1 Q2TB90 3/20 0.43
▸ L3MBTL1 Q9Y468 3/20 0.43
▸ TNNI3 P19429 2/20 0.43
▸ TNNT2 P45379 2/20 0.43
▸ TNNC1 P63316 2/20 0.43
▸ SYNJ2 O15056 2/20 0.43
▸ MAPT P10636 2/20 0.43
▸ RECQL P46063 2/20 0.43
▸ CASP7 P55210 2/20 0.43
▸ NPC1 O15118 1/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ TYR P14679 1/20 0.43
▸ MEN1 O00255 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30852439 1.00 SLC28A3 (0.51) SLC28A3SLC5A1KDM4ETDP1HIF1A
SCHEMBL30852266 1.00 SLC28A3 (0.51) SLC28A3SLC5A1KDM4ETDP1HIF1A
SCHEMBL9018984 0.85 SLC5A1 (0.57) SLC28A3SLC5A1KDM4ETDP1HIF1A
SCHEMBL30852328 0.85 SLC5A1 (0.57) SLC28A3SLC5A1KDM4ETDP1HIF1A
SCHEMBL30852306 0.84 SLC28A3 (0.51) SLC28A3SLC5A1SLC5A2
SCHEMBL30852275 0.84 SLC28A3 (0.51) SLC28A3SLC5A1SLC5A2
SCHEMBL30852313 0.84 SLC28A3 (0.51) SLC28A3SLC5A1SLC5A2
SCHEMBL30852277 0.80 SLC5A1 (0.52) SLC28A3SLC5A1KDM4ETDP1HIF1A
SCHEMBL8081014 0.78 KDM4E (0.53) SLC28A3SLC5A1KDM4ETDP1HIF1A
SCHEMBL2465791 0.78 KDM4E (0.53) SLC28A3SLC5A1KDM4ETDP1HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3349750-B1 PHARMACEUTICAL COMPOUND IOMET PHARMA LTD (GB) 2026-05-13 — — EP disclosed
EP-3215156-B1 INHIBITORS OF TRYPTOPHAN-2,3-DIOXYGENASE OR INDOLEAMINE-2,3-DIOXYGENASE IOMET PHARMA LTD (GB) 2025-09-24 — — EP disclosed
EP-3182972-B1 PHARMACEUTICAL COMPOUND IOMET PHARMA LTD (GB) 2024-01-03 — — EP disclosed
CN-111943890-B Pharmaceutical compounds 艾欧米制药有限公司 2023-10-31 — — CN disclosed
US-20220259212-A1 INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN 2,3-DIOXYGENASE IDORSIA PHARMACEUTICALS LTD (CH) 2022-08-18 — — US disclosed
EP-3997083-A1 INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN 2,3-DIOXYGENASE Idorsia Pharmaceuticals Ltd (CH) 2022-05-18 — — EP disclosed
US-11267824-B2 Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase IDORSIA PHARMACEUTICALS LTD (CH) 2022-03-08 — — US disclosed
CN-114127066-A Inhibitors of indoleamine 2, 3-dioxygenase and/or tryptophan 2, 3-dioxygenase 爱杜西亚药品有限公司 2022-03-01 — — CN disclosed
EP-3740493-B1 INHIBTEURS DE L'INDOLEAMINE 2,3-DIOXYGÉNASE ET/OU DU TRYPTOPHANE DIOXYGÉNASE IDORSIA PHARMACEUTICALS LTD (CH) 2021-12-01 — — EP disclosed
EP-3560928-B1 FUSED IMIDAZOLE COMPOUND HAVING INDOLEAMINE 2,3-DIOXYGENASE INHIBITORY ACTIVITY SHENZHEN CHIPSCREEN BIOSCIENCES CO LTD (CN) 2021-10-20 — — EP disclosed
CN-101784922-A The lightscreening agent that comprises abiogenous chromophore and derivant thereof BENZ RES & DEV CORP 2010-07-21 — — CN disclosed
EP-2130826-A1 Annulins A, B, C or analogs as indoleamine 2,3-dioxygenase (IDO) inhibitors for treatment of cancer The University of British Columbia (CA) 2009-12-09 — — EP disclosed
EP-2130071-A2 LIGHT FILTERS COMPRISING A NATURALLY OCCURRING CHROMOPHORE AND DERIVATIVES THEREOF Benz Research and Development Corporation (US) 2009-12-09 — — EP disclosed
US-20090042868-A1 Indoleamine 2,3-Dioxygenase (IDO) Inhibitors THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2009-02-12 — — US disclosed
EP-1773846-A4 INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS UNIV BRITISH COLUMBIA (CA) 2008-10-08 — — EP disclosed
US-20080242818-A1 LIGHT FILTERS COMPRISING A NATURALLY OCCURRING CHROMOPHORE AND DERIVATIVES THEREOF BENZ RESEARCH AND DEVELOPMENT CORP. 2008-10-02 — — US disclosed
WO-2008109624-A2 LIGHT FILTERS COMPRISING A NATURALLY OCCURRING CHROMOPHORE AND DERIVATIVES THEREOF BENZ RESEARCH AND DEVELOPMENT CORP. (US) 2008-09-12 — — WO disclosed
CN-101098877-A Indoleamine 2,3-dioxygenase (ido) inhibitors UNIV BRITISH COLUMBIA (CA) 2008-01-02 — — CN disclosed
EP-1773846-A1 INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS The University of British Columbia (CA) 2007-04-18 — — EP disclosed
WO-2006005185-A1 INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2006-01-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042868-A1 Indoleamine 2,3-Dioxygenase (IDO) Inhibitors IDO1, IDO2, TDO2 SLC28A3 1965/4885SLC5A1 1558/4885KDM4E 2076/4885
US-20220259212-A1 INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN 2,3-DIOXYGENASE IDO2, TDO2, IDO1 SLC28A3 1542/4885SLC5A1 1256/4885KDM4E 1330/4885
US-11267824-B2 Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase IDO2, IDO1, TDO2 SLC28A3 1603/4885SLC5A1 1473/4885KDM4E 1390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.